Tectonic Launches TX45 Phase 1B Trial for Group 2 PH in HFpEF Patients

Tectonic Therapeutic, a biotech firm, has commenced a Phase 1B clinical trial for TX45, a novel long-acting relaxin-Fc fusion protein, to assess its impact on the cardiovascular system of patients with Group 2 Pulmonary Hypertension (PH), a condition for which no approved treatments currently exist. The company, co-founded by Harvard Medical School professors, is hopeful that TX45's vasodilatory and anti-inflammatory characteristics can lead to better treatment outcomes for these patients. The Phase 1B study will focus on the safety and hemodynamic effects of a single dose of TX45 in patients with PH stemming from heart failure with preserved ejection fraction (HFpEF). This condition affects over 600,000 individuals in the US and is linked to high morbidity and mortality rates. The initial Phase 1A study's promising results suggest that TX45 could be a leading therapy, with further data expected in mid-2024 and Phase 1B results anticipated in 2025. Tectonic Therapeutic is utilizing its proprietary GEODe™ platform to develop innovative treatments for under-served patient populations and is planning a Phase 2 study for the second half of 2024. The company, which is based in Watertown, Massachusetts, is also in the process of merging with AVROBIO, Inc.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!